key: cord-0804961-yyfncfpo authors: Speth, Robert C. title: Response to recent commentaries regarding the involvement of angiotensin‐converting enzyme 2 (ACE2) and renin‐angiotensin system blockers in SARS‐CoV‐2 infections date: 2020-04-17 journal: Drug Dev Res DOI: 10.1002/ddr.21672 sha: a6919e088738bee87642f1f8f9946af741622bf6 doc_id: 804961 cord_uid: yyfncfpo nan icine Blog (Fang, Karakiulakis, & Roth, 2020; Gurwitz, 2020) https:// blogs.sciencemag.org/pipeline/archives/2020/03/17/angiotensin-andthe-coronavirus have addressed the involvement of ACE2 as the receptor for the SARS viruses, raising concerns about the use of angiotensin-converting enzyme inhibitors, (ACE inhibitors, for example, captopril, lisinopril, enalapril, as well as angiotensin receptor blockers (ARBs, for example, losartan, valsartan, telmisartan) in individuals who have hypertension, cardiovascular or renovascular diseases. All three of these publications report that ARBs increase ACE2, either based upon an observation of increased urinary ACE2 (Furuhashi et al., 2015) , a misquote of a recent report (Wan, Shang, Graham, Baric, & Li, 2020) of the interactions of SARS CoV with ACE2 (Fang et al., 2020) , and amplification of this misquote https:// blogs.sciencemag.org/pipeline/archives/2020/03/17/angiotensinand-the-coronavirus. The interpretation of the Furuhashi et al., 2015 (Furuhashi et al., 2015 report, that increased urinary ACE2 indicates an increase in ACE2 synthesis is likely incorrect for three reasons: (a) the increase in urinary ACE2 was only seen with olmesartan. Losartan, candesartan, valsartan and telmisartan did not increase urinary ACE2. (b) Soluble ACE2 is ACE2 that is shed from membranes, reflecting a distinctly different process than ACE2 synthesis. Increased urinary ACE2 suggests a reduction in membrane bound ACE2, indeed, it has been suggested that increased urinary ACE2 is a marker for and might be a causal factor for diseases associated with hyperactivity of the renin-angiotensin system (RAS), such as chronic kidney disease (Palau, Pascual, Soler, & Riera, 2019) . (c) Urinary ACE2 likely reflects proximal tubule ACE2 expressed on the apical side of tubular epithelial cells that has been shed by the actions of ADAM17 (also known as TNFα converting enzyme, TACE, and TNFα convertase) (Palau et al., 2019; Wysocki et al., 2013; Xiao et al., 2014) . The molecular weight of shed ACE2 arising from the cell membranes from healthy individuals is~90 and~120 kDa (Mizuiri et al., 2011) , well above the glomerular filtration limit, so urinary ACE2 would not reflect ACE2 levels outside of the kidney (Wysocki et al., 2013) unless smaller fragments of shed ACE2 that retain immunoreactivity to the ACE2 antibody used in the ELISA assay are present. At this time the effects of ATR1 blockers and ACE inhibitors on membrane bound ACE2 in human lung is unknown, so any suggestion that they increase SARS-CoV-2 infectivity currently lacks a sound rationale (Danser, Epstein, & Batlle, 2020; Vaduganathan et al., 2020) . ACE2 plays an important role in inactivating angiotensin (Ang) II as well as to generate Ang 1-7 (Lazartigues, Feng, & Lavoie, 2007; Warner, Smith, Hooper, & Turner, 2004) , and any reduction in its activity could increase the ability of Ang II to stimulate AT 1 receptors, which mediate both the pressor and proinflammatory actions of Ang II (Forrester et al., 2018; Piqueras & Sanz, 2020; Ranjbar et al., 2019; Zhou, Ando, Macova, Dou, & Saavedra, 2005) as well as reduce formation of Ang 1-7 which is reported to have cytoprotective properties in the lung and its vasculature (Y. Li et al., 2016; Ye & Liu, 2020) . Moreover, it is unlikely that inhibitors of ACE2 activity would significantly compete for the same or overlapping binding sites on ACE2, as the active site of ACE2 is the HEMGH domain at amino acids 374-378, while the putative SARS-CoV-2 spike protein binding domains are amino acids 30-41, 82-84, and 353-357 https://www-ncbi-nlm-nihgov.ezproxylocal.library.nova.edu/protein/NP_001358344.1. Moreover, the binding sites for SARS-CoV-1 on ACE2, which are the same as those reported for SARS-CoV-2 (Walls et al., 2020 ) are reported to not overlap with the substrate binding site of ACE2 based upon the inability of the ACE2 inhibitor MLN-4760 (Dales et al., 2002) to inhibit SARS-CoV-1 binding to ACE2 (F. Li, Li, Farzan, & Harrison, 2005) . Of interest however, is the promising concept of administering exogenous ACE2 coupled with the Fc region of an immunoglobulin as a neutralizing antibody to serve as a decoy receptor and inactivator of SARS-Cov-2 (Kruse, 2020) thereby preventing it from binding to membrane bound Clinical trials of renin-angiotensin system-based therapies (including therapies targeting SARS-Cov-2 ACE2 interactions) listed in clinicaltrials.gov as of April 6, 2020 with cytotoxic targeting of the SARS-CoV-2 virus has recently been registered on ClinicalTrials.gov (Table 1) . Since inflammation is one of the major causes of morbidity of SARS-CoV-2 infection, and AT 1 receptors are known to cause inflammation (Forrester et al., 2018; Piqueras & Sanz, 2020; Ranjbar et al., 2019; Zhou et al., 2005) , AT 1 receptor blockers (ARBs) present an additional therapeutic modality to minimize complications of the respiratory impairments caused by this virus. While ACE inhibitors present an equivalent therapeutic option to ARBs for treatment of hypertension and cardiovascular and renovascular disease, their ability to protect bradykinin from degradation, manifested as the ACE inhibitor cough, as well as the increased risk of angioedema could be a cause for concern (Messerli, Bangalore, Bavishi, & Rimoldi, 2018) . However, ACE inhibitors can increase Ang 1-7 production directly from Ang I via endopeptidase activity (Karamyan & Speth, 2007) and they also protect Ang 1-7 from degradation to the inactive metabolite Ang 1-5 (Chappell, Pirro, Sykes, & Ferrario, 1998) . There is abundant capacity to synthesize Ang II in the lungs as well as AT 1 receptors to mediate its effects (Oakes, Fuchs, Gardner, Lazartigues, & Yue, 2018) . In a mouse model of lung inflammation induced by bacterial lipopolysaccharide, ARBs reportedly reduced the pathological injury (Ye & Liu, 2020) . Gurwitz (2020) noted that there is a large population of individuals who are taking ARBs for treatment of hypertension (Gurwitz, 2020) . There are now several retrospective surveys registered with ClinicalTrials.gov (Table 1) to determine if the use of an ARB or ACE inhibitor is associated with SARS-CoV-2 infections and the degree of morbidity or death compared to individuals taking non-ARB antihypertensive medications that will readily inform us as to the utility of ARBs and ACE inhibitors to ameliorate this disease. As of this writing, The American College of Cardiology, The American Heart Association and the Heart Failure Society of America all recommend that patients with hypertension continue to take ARBs and ACE inhibitors as directed https://www.acc.org/latest-incardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statementaddresses-concerns-re-using-raas-antagonists-in-covid-19 as well as several other biomedical societies listed recently (Vaduganathan et al., 2020) . 4/2/20 Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE inhibitors or ARBs to observe whether antihypertensive ACE inhibitors or ARBs increases the severity of the clinical manifestation of COVID19. Note: As of April 6, 2020 there are 16 trials listed with Clinicaltrials.gov: Three viral decoy studies, one of which has been withdrawn, five ARB therapy studies, one Ang 1-7 (product of ACE2) study, two withdrawal of ACE inhibitor or ARB therapy with or without antihypertensive drug replacement studies, and five retrospective studies of ARB or ACE inhibitor use relationship to COVID infection incidence and morbidity. Different types of studies are separated by shading differences. As of April 13, 2020, there were four additional trials listed with clinicaltrials.gov: one additional ARB therapy trial, one withdrawal of ACEinhibitor/ARB therapy, one retrospective study of ACE inhibitor/ARB therapy, and one study to observe RAS activity in COVID 19 patients. Robert C. Speth https://orcid.org/0000-0002-6434-2136 Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors Renin-angiotensin system blockers and the COVID-19 pandemic Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine Angiotensin II signal transduction: An update on mechanisms of physiology and pathophysiology Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics Enzymatic pathways of the brain renin-angiotensin system: Unsolved problems and continuing challenges Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res, 9 The two fACEs of the tissue renin-angiotensin systems: Implication in cardiovascular diseases Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Angiotensin-converting enzyme 2 prevents lipopolysaccharideinduced rat acute lung injury via suppressing the ERK1/2 and NF-kappaB signaling pathways Angiotensin-converting enzyme inhibitors in hypertension: To use or not to use Urinary angiotensin-converting enzyme 2 in patients with CKD Nicotine and the renin-angiotensin system Role of ADAM17 in kidney disease Angiotensin II and leukocyte trafficking: New insights for an old vascular mediator. Role of redox-signaling pathways The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases Renin-angiotensinaldosterone system inhibitors in patients with Covid-19 Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS Angiotensin-converting enzyme-2: A molecular and cellular perspective Regulation of urinary ACE2 in diabetic mice Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells ACE2 exhibits protective effects against LPSinduced acute lung injury in mice by inhibiting the LPS-TLR4 pathway Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats